Abstract
Metabolic Syndrome (MS) is an amalgamation of symptoms encompassing insulin resistance, obesity, dyslipidemia, elevated fasting blood glucose levels, and hepatic steatosis. Emerging evidence suggests that the hallmark of MS lies in alterations in the composition of the gut microbiota and its metabolites. These alterations traverse a compromised intestinal barrier, exerting an impact on various metabolic organs, thereby precipitating the onset of MS. In recent years, the rapid advancement of sequencing methodologies, bioinformatics, and metagenomic technologies has rendered the exploration of the composition and functionality of the gut microbiota feasible. The manipulation of the gut microbiota is now considered a highly promising novel strategy for the treatment of MS. Ginsenosides, serving as the principal bioactive constituents of the esteemed herb ginseng, have been unequivocally validated to possess a diverse array of pharmacological activities, encompassing anti-inflammatory, antidiabetic, and cardiovascular protective properties. Nevertheless, the intricacies of the therapeutic mechanisms underlying ginsenosides in the treatment of MS remain unclear, owing to the challenge posed by their inherently low absorption rates. Recent studies indicate that when ginsenosides enters the gastrointestinal tract, ginsenosides can interact with the gut microbiota. The gut microbiota may represent a potential mechanism for the therapeutic effects of ginsenosides in treating MS. Based on this, this review aims to summarize the latest research progress of ginsenosides targeting the gut microbiota and its metabolites for the treatment of MS, and provide evidence to confirm that ginsenosides have the potential to become modulators of gut microbiota for the treatment of MS.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Agus A, Clément K, Sokol H (2021) Gut microbiota-derived metabolites as central regulators in metabolic disorders. Gut 70:1174–1182. https://doi.org/10.1136/gutjnl-2020-323071
Al Mahri S, Malik SS, Al Ibrahim M et al (2022) Free fatty acid receptors (FFARs) in adipose: physiological role and therapeutic outlook. Cells 11:750. https://doi.org/10.3390/cells11040750
Almeida A, Nayfach S, Boland M et al (2021) A unified catalog of 204,938 reference genomes from the human gut microbiome. Nat Biotechnol 39:105–114. https://doi.org/10.1038/s41587-020-0603-3
Anhê FF, Barra NG, Cavallari JF et al (2021) Metabolic endotoxemia is dictated by the type of lipopolysaccharide. Cell Rep 36:109691. https://doi.org/10.1016/j.celrep.2021.109691
Aron-Wisnewsky J, Prifti E, Belda E et al (2019) Major microbiota dysbiosis in severe obesity: fate after bariatric surgery. Gut 68:70–82. https://doi.org/10.1136/gutjnl-2018-316103
Atanasov AG, Zotchev SB, Dirsch VM, Supuran CT (2021) Natural products in drug discovery: advances and opportunities. Nat Rev Drug Discov 20:200–216. https://doi.org/10.1038/s41573-020-00114-z
Bäckhed F, Ding H, Wang T et al (2004) The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci U S A 101:15718–15723. https://doi.org/10.1073/pnas.0407076101
Bai X, Fu R, Duan Z et al (2021a) Ginsenoside Rh4 alleviates antibiotic-induced intestinal inflammation by regulating the TLR4-MyD88-MAPK pathway and gut microbiota composition. Food Funct 12:2874–2885. https://doi.org/10.1039/D1FO00242B
Bai X, Fu R, Duan Z et al (2021b) Ginsenoside Rk3 alleviates gut microbiota dysbiosis and colonic inflammation in antibiotic-treated mice. Food Res Int 146:110465. https://doi.org/10.1016/j.foodres.2021.110465
Bai Y, Bao X, Mu Q et al (2021c) Ginsenoside Rb1, salvianolic acid B and their combination modulate gut microbiota and improve glucolipid metabolism in high-fat diet induced obese mice. PeerJ 9:e10598. https://doi.org/10.7717/peerj.10598
Banerjee S, Schlaeppi K, van der Heijden MGA (2018) Keystone taxa as drivers of microbiome structure and functioning. Nat Rev Microbiol 16:567–576. https://doi.org/10.1038/s41579-018-0024-1
Berg G, Rybakova D, Fischer D et al (2020) Microbiome definition re-visited: old concepts and new challenges. Microbiome 8:103. https://doi.org/10.1186/s40168-020-00875-0
Britton GJ, Contijoch EJ, Mogno I et al (2019) Microbiotas from humans with inflammatory bowel disease alter the balance of Gut Th17 and RORγt+ regulatory T cells and exacerbate colitis in mice. Immunity 50:212–224. https://doi.org/10.1016/j.immuni.2018.12.015
Cai J, Sun L, Gonzalez FJ (2022) Gut microbiota-derived bile acids in intestinal immunity, inflammation, and tumorigenesis. Cell Host Microbe 30:289–300. https://doi.org/10.1016/j.chom.2022.02.004
Camargo A, Jimenez-Lucena R, Alcala-Diaz JF et al (2019) Postprandial endotoxemia may influence the development of type 2 diabetes mellitus: from the CORDIOPREV study. Clin Nutr 38:529–538. https://doi.org/10.1016/j.clnu.2018.03.016
Canfora EE, Meex RCR, Venema K, Blaak EE (2019) Gut microbial metabolites in obesity, NAFLD and T2DM. Nat Rev Endocrinol 15:261–273. https://doi.org/10.1038/s41574-019-0156-z
Cani PD (2019) Microbiota and metabolites in metabolic diseases. Nat Rev Endocrinol 15:69–70. https://doi.org/10.1038/s41574-018-0143-9
Castellanos-Jankiewicz A, Guzmán-Quevedo O, Fénelon VS et al (2021) Hypothalamic bile acid-TGR5 signaling protects from obesity. Cell Metab 33:1483–1492. https://doi.org/10.1016/j.cmet.2021.04.009
Chambers ES, Viardot A, Psichas A et al (2015) Effects of targeted delivery of propionate to the human colon on appetite regulation, body weight maintenance and adiposity in overweight adults. Gut 64:1744–1754. https://doi.org/10.1136/gutjnl-2014-307913
Chambers ES, Preston T, Frost G, Morrison DJ (2018) Role of gut microbiota-generated short-chain fatty acids in metabolic and cardiovascular health. Curr Nutr Rep 7:198–206. https://doi.org/10.1007/s13668-018-0248-8
Chávez-Talavera O, Tailleux A, Lefebvre P, Staels B (2017) Bile acid control of metabolism and inflammation in obesity, type 2 diabetes, dyslipidemia, and nonalcoholic fatty liver disease. Gastroenterology 152:1679–1694. https://doi.org/10.1053/j.gastro.2017.01.055
Chen C, Li H, Long Y-Q (2016) GPR40 agonists for the treatment of type 2 diabetes mellitus: the biological characteristics and the chemical space. Bioorg Med Chem Lett 26:5603–5612. https://doi.org/10.1016/j.bmcl.2016.10.074
Chen H, Yang H, Deng J, Fan D (2021) Ginsenoside Rk3 ameliorates obesity-induced colitis by regulating of intestinal flora and the TLR4/NF-κB signaling pathway in C57BL/6 mice. J Agric Food Chem 69:3082–3093. https://doi.org/10.1021/acs.jafc.0c07805
Chen Z, Zhang Z, Liu J et al (2022) Gut microbiota: therapeutic targets of ginseng against multiple disorders and ginsenoside transformation. Front Cell Infect Microbiol 12:853981. https://doi.org/10.3389/fcimb.2022.853981
Chopra P, Chhillar H, Kim Y-J et al (2023) Phytochemistry of ginsenosides: recent advancements and emerging roles. Crit Rev Food Sci Nutr 63:613–640. https://doi.org/10.1080/10408398.2021.1952159
Costa G, Shushanof M, Bouskela E, Bottino D (2021) Oral L-arginine (5 g/day) for 14 days improves microcirculatory function in healthy young women and healthy and type 2 diabetes mellitus elderly women. J Vasc Res 59:24–33. https://doi.org/10.1159/000519428
David LA, Maurice CF, Carmody RN et al (2014) Diet rapidly and reproducibly alters the human gut microbiome. Nature 505:559–563. https://doi.org/10.1038/nature12820
de Aguiar Vallim TQ, Tarling EJ, Edwards PA (2013) Pleiotropic roles of bile acids in metabolism. Cell Metab 17:657–669. https://doi.org/10.1016/j.cmet.2013.03.013
de Wouters DA, Rastelli M, Van Hul M et al (2021) Gut microbes participate in food preference alterations during obesity. Gut Microbes 13:1959242. https://doi.org/10.1080/19490976.2021.1959242
Depommier C, Everard A, Druart C et al (2019) Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study. Nat Med 25:1096–1103. https://doi.org/10.1038/s41591-019-0495-2
Drucker DJ (2018) Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab 27:740–756. https://doi.org/10.1016/j.cmet.2018.03.001
Drucker DJ (2022) GLP-1 physiology informs the pharmacotherapy of obesity. Mol Metab 57:101351. https://doi.org/10.1016/j.molmet.2021.101351
Eckel RH, Grundy SM, Zimmet PZ (2005) The metabolic syndrome lancet. Lond Engl 365:1415–1428. https://doi.org/10.1016/S0140-6736(05)66378-7
Fan Y, Pedersen O (2021) Gut microbiota in human metabolic health and disease. Nat Rev Microbiol 19:55–71. https://doi.org/10.1038/s41579-020-0433-9
Feng R, Shou J-W, Zhao Z-X et al (2015) Transforming berberine into its intestine-absorbable form by the gut microbiota. Sci Rep 5:12155. https://doi.org/10.1038/srep12155
Gangarapu V, Yıldız K, Ince AT, Baysal B (2014) Role of gut microbiota: obesity and NAFLD. Turk J Gastroenterol off J Turk Soc Gastroenterol 25:133–140. https://doi.org/10.5152/tjg.2014.7886
Gradisteanu Pircalabioru G, Ilie I, Oprea L et al (2022) Microbiome, mycobiome and related metabolites alterations in patients with metabolic syndrome—a pilot study. Metabolites 12:218. https://doi.org/10.3390/metabo12030218
Gu W, Kim K-A, Kim D-H (2013) Ginsenoside Rh1 ameliorates high fat diet-induced obesity in mice by inhibiting adipocyte differentiation. Biol Pharm Bull 36:102–107. https://doi.org/10.1248/bpb.b12-00558
Gurung M, Li Z, You H et al (2020) Role of gut microbiota in type 2 diabetes pathophysiology. EBioMedicine 51:102590. https://doi.org/10.1016/j.ebiom.2019.11.051
Habtemariam S (2020) Berberine pharmacology and the gut microbiota: a hidden therapeutic link. Pharmacol Res 155:104722. https://doi.org/10.1016/j.phrs.2020.104722
Han H, Yi B, Zhong R et al (2021) From gut microbiota to host appetite: gut microbiota-derived metabolites as key regulators. Microbiome 9:162. https://doi.org/10.1186/s40168-021-01093-y
Hang S, Paik D, Yao L et al (2019) Bile acid metabolites control TH17 and treg cell differentiation. Nature 576:143–148. https://doi.org/10.1038/s41586-019-1785-z
Haro C, Garcia-Carpintero S, Alcala-Diaz JF et al (2016) The gut microbial community in metabolic syndrome patients is modified by diet. J Nutr Biochem 27:27–31. https://doi.org/10.1016/j.jnutbio.2015.08.011
Harvey AL, Edrada-Ebel R, Quinn RJ (2015) The re-emergence of natural products for drug discovery in the genomics era. Nat Rev Drug Discov 14:111–129. https://doi.org/10.1038/nrd4510
He L, Gomes AP, Wang X et al (2018) mTORC1 Promotes Metabolic Reprogramming by the Suppression of GSK3-Dependent Foxk1 Phosphorylation. Mol Cell 70:949–960. https://doi.org/10.1016/j.molcel.2018.04.024
Henneke L, Schlicht K, Andreani NA et al (2022) A dietary carbohydrate – gut Parasutterella – human fatty acid biosynthesis metabolic axis in obesity and type 2 diabetes. Gut Microbes 14:2057778. https://doi.org/10.1080/19490976.2022.2057778
Hernandez GV, Smith VA, Melnyk M et al (2020) Dysregulated FXR-FGF19 signaling and choline metabolism are associated with gut dysbiosis and hyperplasia in a novel pig model of pediatric NASH. Am J Physiol Gastrointest Liver Physiol 318:G582–G609. https://doi.org/10.1152/ajpgi.00344.2019
Holter MM, Chirikjian MK, Govani VN, Cummings BP (2020) TGR5 signaling in hepatic metabolic health. Nutrients 12:2598. https://doi.org/10.3390/nu12092598
Hong Y, Lin Y, Si Q et al (2019) Ginsenoside Rb2 alleviates obesity by activation of brown fat and induction of browning of white fat. Front Endocrinol 10:153. https://doi.org/10.3389/fendo.2019.00153
Hong C, Liang J, Xia J et al (2020) One stone four birds: a novel liposomal delivery system multi-functionalized with ginsenoside Rh2 for tumor targeting therapy. Nano-Micro Lett 12:129. https://doi.org/10.1007/s40820-020-00472-8
Hong JT, Lee M-J, Yoon SJ et al (2021) Effect of Korea red ginseng on nonalcoholic fatty liver disease: an association of gut microbiota with liver function. J Ginseng Res 45:316–324. https://doi.org/10.1016/j.jgr.2020.07.004
Hou K, Wu Z-X, Chen X-Y et al (2022) Microbiota in health and diseases. Signal Transduct Target Ther 7:1–28. https://doi.org/10.1038/s41392-022-00974-4
Hu S, Han M, Rezaei A et al (2017) L-arginine modulates glucose and lipid metabolism in obesity and diabetes. Curr Protein Pept Sci 18:599–608. https://doi.org/10.2174/1389203717666160627074017
Islam MdM, Islam MdM, Rahman MdA et al (2023) Gut microbiota in obesity and related complications: unveiling the complex interplay. Life Sci 334:122211. https://doi.org/10.1016/j.lfs.2023.122211
Jaacks LM, Vandevijvere S, Pan A et al (2019) The obesity transition: stages of the global epidemic. Lancet Diabetes Endocrinol 7:231–240. https://doi.org/10.1016/S2213-8587(19)30026-9
Jeepipalli SPK, Du B, Sabitaliyevich UY, Xu B (2020) New insights into potential nutritional effects of dietary saponins in protecting against the development of obesity. Food Chem 318:126474. https://doi.org/10.1016/j.foodchem.2020.126474
Johnson KV-A, Foster KR (2018) Why does the microbiome affect behaviour? Nat Rev Microbiol 16:647–655. https://doi.org/10.1038/s41579-018-0014-3
Karlsson FH, Tremaroli V, Nookaew I et al (2013) Gut metagenome in European women with normal, impaired and diabetic glucose control. Nature 498:99–103. https://doi.org/10.1038/nature12198
Kim CH (2018a) Microbiota or short-chain fatty acids: Which regulates diabetes? Cell Mol Immunol 15:88–91. https://doi.org/10.1038/cmi.2017.57
Kim D-H (2018b) Gut microbiota-mediated pharmacokinetics of ginseng saponins. J Ginseng Res 42:255–263. https://doi.org/10.1016/j.jgr.2017.04.011
Kim K, Park M, Lee YM et al (2014) Ginsenoside metabolite compound K stimulates glucagon-like peptide-1 secretion in NCI-H716 cells via bile acid receptor activation. Arch Pharm Res 37:1193–1200. https://doi.org/10.1007/s12272-014-0362-0
Koh A, Molinaro A, Ståhlman M et al (2018) Microbially produced imidazole propionate impairs insulin signaling through mTORC1. Cell 175:947–961. https://doi.org/10.1016/j.cell.2018.09.055
Krautkramer KA, Fan J, Bäckhed F (2021) Gut microbial metabolites as multi-kingdom intermediates. Nat Rev Microbiol 19:77–94. https://doi.org/10.1038/s41579-020-0438-4
Kriss M, Hazleton KZ, Nusbacher NM et al (2018) Low diversity gut microbiota dysbiosis: drivers, functional implications and recovery. Curr Opin Microbiol 44:34–40. https://doi.org/10.1016/j.mib.2018.07.003
Kuhre RE, Wewer Albrechtsen NJ, Larsen O et al (2018) Bile acids are important direct and indirect regulators of the secretion of appetite- and metabolism-regulating hormones from the gut and pancreas. Mol Metab 11:84–95. https://doi.org/10.1016/j.molmet.2018.03.007
Li W, Hang S, Fang Y et al (2021) A bacterial bile acid metabolite modulates Treg activity through the nuclear hormone receptor NR4A1. Cell Host Microbe 29:1366–1377. https://doi.org/10.1016/j.chom.2021.07.013
Li X, Liu J, Zuo T et al (2022) Advances and challenges in ginseng research from 2011 to 2020: the phytochemistry, quality control, metabolism, and biosynthesis. Nat Prod Rep 39:875–909. https://doi.org/10.1039/D1NP00071C
Li P, Jiang J, Li Y et al (2023) Metagenomic analysis reveals distinct changes in the gut microbiome of obese Chinese children. BMC Genom 24:721. https://doi.org/10.1186/s12864-023-09805-4
Liang W, Zhou K, Jian P et al (2021) Ginsenosides improve nonalcoholic fatty liver disease via integrated regulation of gut microbiota, inflammation and energy homeostasis. Front Pharmacol 12:48. https://doi.org/10.3389/fphar.2021.622841
Lin M, Jiang M, Yang T et al (2022) Overexpression of GPR41 attenuated glucose production in propionate-induced bovine hepatocytes. Front Vet Sci 9:981640
Liu R, Hong J, Xu X et al (2017) Gut microbiome and serum metabolome alterations in obesity and after weight-loss intervention. Nat Med 23:859–868. https://doi.org/10.1038/nm.4358
Liu Z, Qin G, Mana L et al (2020) GAPT regulates cholinergic dysfunction and oxidative stress in the brains of learning and memory impairment mice induced by scopolamine. Brain Behav 10:e01602. https://doi.org/10.1002/brb3.1602
Liu L, Zhang J, Cheng Y et al (2022) Gut microbiota: a new target for T2DM prevention and treatment. Front Endocrinol 13:958218
Liu B, Zhang L, Yang H et al (2023) Microbiota: a potential orchestrator of antidiabetic therapy. Front Endocrinol 14:973624
Lo BC, Kryczek I, Yu J et al (2024) Microbiota-dependent activation of CD4+ T cells induces CTLA-4 blockade–associated colitis via Fcγ receptors. Science 383:62–70. https://doi.org/10.1126/science.adh8342
Lu Y, Fan C, Li P et al (2016) Short chain fatty acids prevent high-fat-diet-induced obesity in mice by regulating G protein-coupled receptors and gut microbiota. Sci Rep 6:37589. https://doi.org/10.1038/srep37589
Luo Z, Xu W, Zhang Y et al (2020) A review of saponin intervention in metabolic syndrome suggests further study on intestinal microbiota. Pharmacol Res 160:105088. https://doi.org/10.1016/j.phrs.2020.105088
Lynch CJ, Adams SH (2014) Branched-chain amino acids in metabolic signalling and insulin resistance. Nat Rev Endocrinol 10:723–736. https://doi.org/10.1038/nrendo.2014.171
Lynch SV, Pedersen O (2016) The human intestinal microbiome in health and disease. N Engl J Med 375:2369–2379. https://doi.org/10.1056/NEJMra1600266
Ma C, Han M, Heinrich B et al (2018) Gut microbiome–mediated bile acid metabolism regulates liver cancer via NKT cells. Science 360:eaan5931. https://doi.org/10.1126/science.aan5931
Magne F, Gotteland M, Gauthier L et al (2020) The firmicutes/bacteroidetes ratio: A relevant marker of gut dysbiosis in obese patients? Nutrients 12:1474. https://doi.org/10.3390/nu12051474
McGavigan AK, Garibay D, Henseler ZM et al (2017) TGR5 contributes to glucoregulatory improvements after vertical sleeve gastrectomy in mice. Gut 66:226–234. https://doi.org/10.1136/gutjnl-2015-309871
Metwaly A, Reitmeier S, Haller D (2022) Microbiome risk profiles as biomarkers for inflammatory and metabolic disorders. Nat Rev Gastroenterol Hepatol 19:383–397. https://doi.org/10.1038/s41575-022-00581-2
Molinaro A, Bel Lassen P, Henricsson M et al (2020) Imidazole propionate is increased in diabetes and associated with dietary patterns and altered microbial ecology. Nat Commun 11:5881. https://doi.org/10.1038/s41467-020-19589-w
Morais LH, Schreiber HL, Mazmanian SK (2021) The gut microbiota–brain axis in behaviour and brain disorders. Nat Rev Microbiol 19:241–255. https://doi.org/10.1038/s41579-020-00460-0
Mu Q, Zuo J, Zhao D et al (2021) Ginsenoside rg3 reduces body weight by regulating fat content and browning in obese mice. J Tradit Chin Med Sci 8:65–71. https://doi.org/10.1016/j.jtcms.2021.01.009
Nakamura MT, Yudell BE, Loor JJ (2014) Regulation of energy metabolism by long-chain fatty acids. Prog Lipid Res 53:124–144. https://doi.org/10.1016/j.plipres.2013.12.001
Nolan PB, Carrick-Ranson G, Stinear JW et al (2017) Prevalence of metabolic syndrome and metabolic syndrome components in young adults: a pooled analysis. Prev Med Rep 7:211–215. https://doi.org/10.1016/j.pmedr.2017.07.004
Noubiap JJ, Nansseu JR, Lontchi-Yimagou E et al (2022) Geographic distribution of metabolic syndrome and its components in the general adult population: a meta-analysis of global data from 28 million individuals. Diabetes Res Clin Pract 188:109924. https://doi.org/10.1016/j.diabres.2022.109924
Offermanns S (2014) Free fatty acid (FFA) and hydroxy carboxylic acid (HCA) receptors. Annu Rev Pharmacol Toxicol 54:407–434. https://doi.org/10.1146/annurev-pharmtox-011613-135945
Org E, Blum Y, Kasela S et al (2017) Relationships between gut microbiota, plasma metabolites, and metabolic syndrome traits in the METSIM cohort. Genome Biol 18:70. https://doi.org/10.1186/s13059-017-1194-2
Pathak P, Xie C, Nichols RG et al (2018) Intestine farnesoid X receptor agonist and the gut microbiota activate G-protein bile acid receptor-1 signaling to improve metabolism. Hepatology 68:1574–1588. https://doi.org/10.1002/hep.29857
Pendyala S, Walker JM, Holt PR (2012) A high-fat diet is associated with endotoxemia that originates from the gut. Gastroenterology 142:1100. https://doi.org/10.1053/j.gastro.2012.01.034
Peng M, Wang L, Su H et al (2022) Ginsenoside Rg1 improved diabetes through regulating the intestinal microbiota in high-fat diet and streptozotocin-induced type 2 diabetes rats. J Food Biochem 46:e14321. https://doi.org/10.1111/jfbc.14321
Perino A, Schoonjans K (2022) Metabolic messengers: bile acids. Nat Metab 4:416–423. https://doi.org/10.1038/s42255-022-00559-z
Petersen N, Frimurer TM, Terndrup Pedersen M et al (2018) Inhibiting RHOA signaling in mice increases glucose tolerance and numbers of enteroendocrine and other secretory cells in the intestine. Gastroenterology 155:1164–1176. https://doi.org/10.1053/j.gastro.2018.06.039
Prawitt J, Abdelkarim M, Stroeve JHM et al (2011) Farnesoid X receptor deficiency improves glucose homeostasis in mouse models of obesity. Diabetes 60:1861–1871. https://doi.org/10.2337/db11-0030
Qin J, Li Y, Cai Z et al (2012) A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature 490:55–60. https://doi.org/10.1038/nature11450
Quan L-H, Zhang C, Dong M et al (2020) Myristoleic acid produced by enterococci reduces obesity through brown adipose tissue activation. Gut 69:1239–1247. https://doi.org/10.1136/gutjnl-2019-319114
Quinn RA, Melnik AV, Vrbanac A et al (2020) Global chemical effects of the microbiome include new bile-acid conjugations. Nature 579:123–129. https://doi.org/10.1038/s41586-020-2047-9
Rastelli M, Cani PD, Knauf C (2019) The gut microbiome influences host endocrine functions. Endocr Rev 40:1271–1284. https://doi.org/10.1210/er.2018-00280
Rehman K, Haider K, Jabeen K, Akash MSH (2020) Current perspectives of oleic acid: regulation of molecular pathways in mitochondrial and endothelial functioning against insulin resistance and diabetes. Rev Endocr Metab Disord 21:631–643. https://doi.org/10.1007/s11154-020-09549-6
Ridaura VK, Faith JJ, Rey FE et al (2013) Gut microbiota from twins discordant for obesity modulate metabolism in mice. Science 341:1241214. https://doi.org/10.1126/science.1241214
Roh E, Hwang H-J, Kim JW et al (2020) Ginsenoside Mc1 improves liver steatosis and insulin resistance by attenuating ER stress. J Ethnopharmacol 259:112927. https://doi.org/10.1016/j.jep.2020.112927
Saklayen MG (2018) The global epidemic of the metabolic syndrome. Curr Hypertens Rep 20:12. https://doi.org/10.1007/s11906-018-0812-z
Sanders ME, Merenstein DJ, Reid G et al (2019) Probiotics and prebiotics in intestinal health and disease: from biology to the clinic. Nat Rev Gastroenterol Hepatol 16:605–616. https://doi.org/10.1038/s41575-019-0173-3
Sanna S, van Zuydam NR, Mahajan A et al (2019) Causal relationships among the gut microbiome, short-chain fatty acids and metabolic diseases. Nat Genet 51:600–605. https://doi.org/10.1038/s41588-019-0350-x
Schroeder BO, Bäckhed F (2016) Signals from the gut microbiota to distant organs in physiology and disease. Nat Med 22:1079–1089. https://doi.org/10.1038/nm.4185
Schwabe RF, Jobin C (2013) The microbiome and cancer. Nat Rev Cancer 13:800–812. https://doi.org/10.1038/nrc3610
Sears CL, Garrett WS (2014) Microbes, microbiota, and colon cancer. Cell Host Microbe 15:317–328. https://doi.org/10.1016/j.chom.2014.02.007
Sender R, Fuchs S, Milo R (2016) Are we really vastly outnumbered? Revisiting the ratio of bacterial to host cells in humans. Cell 164:337–340. https://doi.org/10.1016/j.cell.2016.01.013
Seong E, Bose S, Han S-Y et al (2021) Positive influence of gut microbiota on the effects of Korean red ginseng in metabolic syndrome: a randomized, double-blind, placebo-controlled clinical trial. EPMA J 12:177–197. https://doi.org/10.1007/s13167-021-00243-4
Siebler J, Galle PR, Weber MM (2008) The gut–liver-axis: endotoxemia, inflammation, insulin resistance and NASH. J Hepatol 48:1032–1034. https://doi.org/10.1016/j.jhep.2008.03.007
Simon J-C, Marchesi JR, Mougel C, Selosse M-A (2019) Host-microbiota interactions: from holobiont theory to analysis. Microbiome 7:5. https://doi.org/10.1186/s40168-019-0619-4
Skelly AN, Sato Y, Kearney S, Honda K (2019) Mining the microbiota for microbial and metabolite-based immunotherapies. Nat Rev Immunol 19:305–323. https://doi.org/10.1038/s41577-019-0144-5
Soderborg TK, Clark SE, Mulligan CE et al (2018) The gut microbiota in infants of obese mothers increases inflammation and susceptibility to NAFLD. Nat Commun 9:4462. https://doi.org/10.1038/s41467-018-06929-0
Sommer F, Anderson JM, Bharti R et al (2017) The resilience of the intestinal microbiota influences health and disease. Nat Rev Microbiol 15:630–638. https://doi.org/10.1038/nrmicro.2017.58
Song M-Y, Kim B-S, Kim H (2014) Influence of Panax ginseng on obesity and gut microbiota in obese middle-aged Korean women. J Ginseng Res 38:106–115. https://doi.org/10.1016/j.jgr.2013.12.004
Sorokina M, Steinbeck C (2020) Review on natural products databases: where to find data in 2020. J Cheminformat 12:20. https://doi.org/10.1186/s13321-020-00424-9
Staley C, Weingarden AR, Khoruts A, Sadowsky MJ (2017) Interaction of gut microbiota with bile acid metabolism and its influence on disease states. Appl Microbiol Biotechnol 101:47–64. https://doi.org/10.1007/s00253-016-8006-6
Sun Y, Chen S, Wei R et al (2018) Metabolome and gut microbiota variation with long-term intake of Panax ginseng extracts on rats. Food Funct 9:3547–3556. https://doi.org/10.1039/C8FO00025E
Sun D, Zou Y, Song L et al (2022) A cyclodextrin-based nanoformulation achieves co-delivery of ginsenoside Rg3 and quercetin for chemo-immunotherapy in colorectal cancer. Acta Pharm Sin B 12:378–393. https://doi.org/10.1016/j.apsb.2021.06.005
Takeuchi T, Kameyama K, Miyauchi E et al (2023) Fatty acid overproduction by gut commensal microbiota exacerbates obesity. Cell Metab 35:361–375. https://doi.org/10.1016/j.cmet.2022.12.013
Taylor SA, Green RM (2018) Bile acids, microbiota, and metabolism. Hepatology 68:1229. https://doi.org/10.1002/hep.30078
Tian F, Wang X, Ni H et al (2021) The ginsenoside metabolite compound K stimulates glucagon-like peptide-1 secretion in NCI–H716 cells by regulating the RhoA/ROCKs/YAP signaling pathway and cytoskeleton formation. J Pharmacol Sci 145:88–96. https://doi.org/10.1016/j.jphs.2020.11.005
Tian F, Huang S, Xu W et al (2022) Compound K attenuates hyperglycemia by enhancing glucagon-like peptide-1 secretion through activating TGR5 via the remodeling of gut microbiota and bile acid metabolism. J Ginseng Res 46:780–789. https://doi.org/10.1016/j.jgr.2022.03.006
Tilg H, Adolph TE, Dudek M, Knolle P (2021) Non-alcoholic fatty liver disease: the interplay between metabolism, microbes and immunity. Nat Metab 3:1596–1607. https://doi.org/10.1038/s42255-021-00501-9
Tolhurst G, Heffron H, Lam YS et al (2012) Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein–coupled receptor FFAR2. Diabetes 61:364–371. https://doi.org/10.2337/db11-1019
Van Hul M, Cani PD (2023) The gut microbiota in obesity and weight management: Microbes as friends or foe? Nat Rev Endocrinol. https://doi.org/10.1038/s41574-022-00794-0
Velazquez-Villegas LA, Perino A, Lemos V et al (2018) TGR5 signalling promotes mitochondrial fission and beige remodelling of white adipose tissue. Nat Commun 9:245. https://doi.org/10.1038/s41467-017-02068-0
Walker AW, Parkhill J (2013) Fighting obesity with bacteria. Science 341:1069–1070. https://doi.org/10.1126/science.1243787
Wang Z, Klipfell E, Bennett BJ et al (2011) Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 472:57–63. https://doi.org/10.1038/nature09922
Watterson KR, Hudson BD, Ulven T, Milligan G (2014) Treatment of type 2 diabetes by free fatty acid receptor agonists. Front Endocrinol 5:137. https://doi.org/10.3389/fendo.2014.00137
Wei Y, Yang H, Zhu C et al (2020) Hypoglycemic effect of ginsenoside Rg5 mediated partly by modulating gut microbiota dysbiosis in diabetic db/db mice. J Agric Food Chem 68:5107–5117. https://doi.org/10.1021/acs.jafc.0c00605
Wong SH, Yu J (2019) Gut microbiota in colorectal cancer: mechanisms of action and clinical applications. Nat Rev Gastroenterol Hepatol 16:690–704. https://doi.org/10.1038/s41575-019-0209-8
Wong AST, Che C-M, Leung K-W (2015) Recent advances in ginseng as cancer therapeutics: a functional and mechanistic overview. Nat Prod Rep 32:256–272. https://doi.org/10.1039/C4NP00080C
Wu H, Tremaroli V, Schmidt C et al (2020) The gut microbiota in prediabetes and diabetes: a population-based cross-sectional study. Cell Metab 32:379–390. https://doi.org/10.1016/j.cmet.2020.06.011
Xi Y, Li H (2020) Role of farnesoid X receptor in hepatic steatosis in nonalcoholic fatty liver disease. Biomed Pharmacother 121:109609. https://doi.org/10.1016/j.biopha.2019.109609
Xie B, Zu X, Wang Z et al (2022a) Ginsenoside Rc ameliorated atherosclerosis via regulating gut microbiota and fecal metabolites. Front Pharmacol 13:990476. https://doi.org/10.3389/fphar.2022.990476
Xu J, Li T, Xia X et al (2020a) Dietary ginsenoside T19 supplementation regulates glucose and lipid metabolism via AMPK and PI3K pathways and its effect on intestinal microbiota. J Agric Food Chem 68:14452–14462. https://doi.org/10.1021/acs.jafc.0c04429
Xu Y, Wang N, Tan H-Y et al (2020b) Panax notoginseng saponins modulate the gut microbiota to promote thermogenesis and beige adipocyte reconstruction via leptin-mediated AMPKα/STAT3 signaling in diet-induced obesity. Theranostics 10:11302–11323. https://doi.org/10.7150/thno.47746
Xu Y, Zhu Y, Li X, Sun B (2020c) Dynamic balancing of intestinal short-chain fatty acids: The crucial role of bacterial metabolism. Trends Food Sci Technol 100:118–130. https://doi.org/10.1016/j.tifs.2020.02.026
Yamamoto K, Yamashita M, Oda M et al (2023) Oral administration of lipopolysaccharide enhances insulin signaling-related factors in the KK/Ay mouse model of type 2 diabetes mellitus. Int J Mol Sci 24:4619. https://doi.org/10.3390/ijms24054619
Yang Q, Vijayakumar A, Kahn BB (2018) Metabolites as regulators of insulin sensitivity and metabolism. Nat Rev Mol Cell Biol 19(10):654–672. https://doi.org/10.1038/s41580-018-0044-8
Yang X, Dong B, An L et al (2021) Ginsenoside Rb1 ameliorates Glycemic disorder in mice with high fat diet-induced obesity via regulating gut microbiota and amino acid metabolism. Front Pharmacol 12:756491
Yang S, Duan Z, Zhang S et al (2023) Ginsenoside Rh4 improves hepatic lipid metabolism and inflammation in a model of NAFLD by targeting the gut liver axis and modulating the FXR signaling pathway. Foods 12:2492. https://doi.org/10.3390/foods12132492
Yu D, Richardson NE, Green CL et al (2021) The adverse metabolic effects of branched-chain amino acids are mediated by isoleucine and valine. Cell Metab 33:905–922. https://doi.org/10.1016/j.cmet.2021.03.025
Zeevi D, Korem T, Godneva A et al (2019) Structural variation in the gut microbiome associates with host health. Nature 568:43–48. https://doi.org/10.1038/s41586-019-1065-y
Zhang L, Qin Q, Liu M et al (2018) Akkermansia muciniphila can reduce the damage of gluco/lipotoxicity, oxidative stress and inflammation, and normalize intestine microbiota in streptozotocin-induced diabetic rats. Pathog Dis 76:fty028. https://doi.org/10.1093/femspd/fty028
Zhang J, Liu M, Huang M et al (2019) Ginsenoside F1 promotes angiogenesis by activating the IGF-1/IGF1R pathway. Pharmacol Res 144:292–305. https://doi.org/10.1016/j.phrs.2019.04.021
Zhang J, Hu K, Di L et al (2021) Traditional herbal medicine and nanomedicine: converging disciplines to improve therapeutic efficacy and human health. Adv Drug Deliv Rev 178:113964. https://doi.org/10.1016/j.addr.2021.113964
Zhao L (2013) The gut microbiota and obesity: from correlation to causality. Nat Rev Microbiol 11:639–647. https://doi.org/10.1038/nrmicro3089
Zhao W, Xiao M, Yang J et al (2019) The combination of Ilexhainanoside D and ilexsaponin A1 reduces liver inflammation and improves intestinal barrier function in mice with high-fat diet-induced non-alcoholic fatty liver disease. Phytomedicine 63:153039. https://doi.org/10.1016/j.phymed.2019.153039
Zhao L, Wang S, Zhang N et al (2022) The beneficial effects of natural extracts and bioactive compounds on the gut-liver axis: a promising intervention for alcoholic liver disease. Antioxid Basel Switz 11:1211. https://doi.org/10.3390/antiox11061211
Zheng Y, Ley SH, Hu FB (2018) Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol 14:88–98. https://doi.org/10.1038/nrendo.2017.151
Zhernakova DV, Wang D, Liu L et al (2024) Host genetic regulation of human gut microbial structural variation. Nature. https://doi.org/10.1038/s41586-023-06893-w
Zhou M, Shao J, Wu C-Y et al (2019) Targeting BCAA catabolism to treat obesity-associated insulin resistance. Diabetes 68:1730–1746. https://doi.org/10.2337/db18-0927
Zhou N, Gu X, Zhuang T et al (2020) Gut microbiota: a pivotal hub for polyphenols as antidepressants. J Agric Food Chem 68:6007–6020. https://doi.org/10.1021/acs.jafc.0c01461
Zhou R, He D, Zhang H et al (2023) Ginsenoside Rb1 protects against diabetes-associated metabolic disorders in Kkay mice by reshaping gut microbiota and fecal metabolic profiles. J Ethnopharmacol 303:115997. https://doi.org/10.1016/j.jep.2022.115997
Zhu W, Gregory JC, Org E et al (2016) Gut microbial metabolite TMAO enhances platelet hyperreactivity and thrombosis risk. Cell 165:111–124. https://doi.org/10.1016/j.cell.2016.02.011
Zhu L-R, Li S-S, Zheng W-Q et al (2023) Targeted modulation of gut microbiota by traditional Chinese medicine and natural products for liver disease therapy. Front Immunol 14:1086078. https://doi.org/10.3389/fimmu.2023.1086078
Zhuang R, Ge X, Han L et al (2019) Gut microbe–generated metabolite trimethylamine N-oxide and the risk of diabetes: a systematic review and dose-response meta-analysis. Obes Rev 20:883–894. https://doi.org/10.1111/obr.12843
Zhuang T, Li W, Yang L et al (2021) Gut microbiota: novel therapeutic target of ginsenosides for the treatment of obesity and its complications. Front Pharmacol 12:731288. https://doi.org/10.3389/fphar.2021.731288
Zou H, Zhang M, Zhu X et al (2022) Ginsenoside Rb1 improves metabolic disorder in high-fat diet-induced obese mice associated with modulation of gut microbiota. Front Microbiol 13:826487. https://doi.org/10.3389/fmicb.2022.826487
Acknowledgements
This work was supported by the National Key Research and Development Program (2019YFA0905200, 2021YFC2103900), National Natural Science Foundation of China (22278335) and Natural Science Basic Research Program of Shaanxi (2023-JC-JQ-17).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Conflict of interest
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Bai, X., Fu, R., Deng, J. et al. New dawn of ginsenosides: regulating gut microbiota to treat metabolic syndrome. Phytochem Rev (2024). https://doi.org/10.1007/s11101-024-09920-4
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s11101-024-09920-4